The present disclosure involves a method and nutritional composition for improving the microbiome and metabolic profile of a pediatric subject, which includes administering to a pediatric subject a composition having up to about 7 g/100 kCal of a protein or protein equivalent source; up to about 7 g/100 kCal of a fat or lipid source; at least about 5 g/100 kCal of a carbohydrate; at least about 0.05 mg/100 kCal of bacterial metabolites; and either a probiotic or a prebiotic composition, or both.
The present disclosure generally provides nutritional compositions that are useful for promoting beneficial bacteria in the gastrointestinal tract of a Cesarean-section (C-section)-delivered infant. The nutritional composition can include a prebiotic composition comprising human milk oligosaccharides (HMO), milk fat globule membrane (MFGM), and galacto-oligosaccharides (GOS) and/or polydextrose (PDX). The present disclosure also provides methods for promoting the growth of beneficial microbiota in the gastrointestinal tract of C-section-delivered infants comprising administering to a C-section-delivered infant the disclosed nutritional composition.
A23C 9/20 - Produits diététiques à base de lait non couverts par les groupes
A23C 9/127 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant des micro-organismes de la famille des lactobactériacées et d'autres micro-organismes ou des enzymes, p. ex. kéfir, koumiss
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
3.
USES OF COMPOSITIONS COMPRISING A PREBIOTIC COMPONENT
A composition for use in improving sleep duration, improving sleep quality, reducing stress, enhancing mood and/or improving cognitive function in an adult is described. The composition comprises a prebiotic component comprising polydextrose (PDX) and galactooligosaccharides (GOS).
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/688 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols les deux composés hydroxylés ayant des atomes d'azote, p. ex. sphingomyélines
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A synthetic nutritional composition for human consumption is described comprising a whey protein concentrate from bovine milk, wherein the whey protein concentrate comprises: a milk fat content of between 6.5 to 10.0 wt %, wherein the milk fat contains components of milk fat globule membranes that provide at least 7 mg/g of sphingomyelin to the whey protein concentrate; and wherein the majority of the sphingomyelin in the synthetic nutritional composition is provided by the components of the milk fat globule membranes of the whey protein concentrate. Methods of making same are also described.
The present disclosure relates generally to methods and nutritional compositions for promoting or maintaining postpartum maternal health. The nutritional composition can include sialyllactose, a source of long chain polyunsaturated fatty acids (“LCPUFAs”), a probiotic, such as Lactobacillus rhamnosus GG (LGG), a nut extract, turmeric, fenugreek calcium and/or vitamin D. The nutritional composition is suitable for administration to postpartum mothers. Additionally, the disclosure provides methods for preventing or reducing the severity of postpartum depression and/or anxiety. The nutritional composition(s) provided herein can comprise various combinations of ingredients that provide additive and or/synergistic beneficial health effects to postpartum mothers.
A23C 9/20 - Produits diététiques à base de lait non couverts par les groupes
A23C 11/10 - Succédanés du lait, p. ex. compositions pour remplacer le lait dans le café au lait contenant au moins un composé d'origine non laitière comme source de matières grasses ou de protéines contenant ou non du lactose mais pas d'autres composés d'origine laitière comme sources de matières grasses, d'hydrates de carbone ou de protéines
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/16 - Sels inorganiques, minéraux ou oligo-éléments
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/59 - Composés contenant le système cyclique du 9,10-séco-cyclopenta[a]hydrophénanthrène
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 33/06 - Aluminium, calcium ou magnésiumLeurs composés
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses)CaesalpiniaceaeMimosaceaePapilionaceae
A61K 36/9066 - Curcuma, p. ex. curcuma, zédoaire ou curcuma amada
6.
COMPOSITIONS AND METHODS FOR PRESERVING PROBIOTIC VIABILITY
The present application provides compositions and methods comprising milk fat globule membrane (MFGM) for use in preserving probiotic viability and/or improving probiotic tolerance to bile stress.
A synthetic nutritional composition for an infant and/or a child is described comprising a whey protein concentrate from milk, wherein the whey protein concentrate comprises: a milk fat content of between 6.5 to 10.0 wt %, wherein the milk fat contains components of milk fat globule membranes that provide at least 7 mg/g of sphingomyelin to the whey protein concentrate; and wherein the majority of the sphingomyelin in the synthetic nutritional composition is provided by the components of the milk fat globule membranes of the whey protein concentrate. Methods of making same are also described.
Provided are nutritional compositions having a decreased protein content. Further disclosed are nutritional composition having a protein or protein equivalent source that includes intact protein, beta-casein enriched casein hydrolysate, and/or amino acids. The nutritional compositions disclosed are suitable for administration to pediatric subjects, such as infants.
The present application provides a synthetic nutritional composition comprising milk fat globule membrane (MFGM) in the range of about 10 μg/100 kcal to about 1500 mg/100 kcal for use in improving neurological development in a paediatric subject. The synthetic nutritional composition is administered to the paediatric subject for at least three months during the first year of life and said administration of the synthetic nutritional composition improves neurological development of the paediatric subject from at least two years of age.
A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
The present application provides lactoferrin, and compositions comprising lactoferrin, for use in the treatment and/or prevention of the 2019 novel coronavirus (COVID-19) infection in a subject.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
12.
STAGED NUTRITIONAL COMPOSITIONS CONTAINING HUMAN MILK OLIGOSACCHARIDES AND USES THEREOF
The present application provides nutritional compositions comprising human milk oligosaccharides, for use in providing nutrition to infants at different age stages.
The present disclosure provides a method and nutritional composition for improving the microbiome and metabolic profile of a pediatric subject, which includes administering to a pediatric subject a composition having up to about 7 g/100 kCal of a protein or protein equivalent source; up to about 7 g/100 kCal of a fat or lipid source; at least about 5 g/100 kCal of a carbohydrate; at least about 0.05 mg/100 kCal of bacterial metabolites produced by microbiota fermentation; and either a probiotic or a prebiotic composition, or both.
The present disclosure generally relates to personalized nutritional compositions for pediatric subjects, wherein the nutritional composition can include one of three distinct profiles of human milk oligosaccharides (HMOs). The present disclosure also relates to methods for determining the composition of HMOs present in or that would be present in the breast milk of the mother of a pediatric subject as determined by the mother's secretor status and/or Lewis blood group, and providing to the pediatric subject a nutritional composition comprising an HMO profile most similar to the HMOs present or that would be present in the breast milk of the subject's mother.
Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for reducing the incidence of obesity and metabolic syndrome in a target subject via administering the nutritional composition containing dietary butyrate to the target subject. Further provided are methods for improving adipose tissue functioning in a target subject.
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
The present application provides lactoferrin, and compositions comprising lactoferrin, for use in the treatment and/or prevention of the 2019 novel coronavirus (COVID-19) infection in a subject.
The present application provides lactoferrin, and compositions comprising lactoferrin, for use in the treatment and/or prevention of the 2019 novel coronavirus (COVID-19) infection in a subject.
The present disclosure generally relates to methods of preparing protein hydrolysates for use in pediatric nutritional compositions. Specifically, alpha-, beta- and/or kappa casein enriched casein, acid casein or caseinates can be hydrolyzed with proteases such as trypsin (trypsin-like), chymotrypsin (chymotrypsin-like), pepsin and/or plasmin to produce a hydrolysate that is close to the peptide composition of human breast milk.
Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
The present disclosure generally provides nutritional compositions that are useful for promoting beneficial bacteria in the gastrointestinal tract of a Cesarean-section (C-section)-delivered infant. The nutritional composition can include a prebiotic composition comprising human milk oligosaccharides (HMO), milk fat globule membrane (MFGM), and galacto-oligosaccharides (GOS) and/or polydextrose (PDX). The present disclosure also provides methods for promoting the growth of beneficial microbiota in the gastrointestinal tract of C-section-delivered infants comprising administering to a C-section-delivered infant the disclosed nutritional composition.
A23C 9/20 - Produits diététiques à base de lait non couverts par les groupes
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
A23C 9/127 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant des micro-organismes de la famille des lactobactériacées et d'autres micro-organismes ou des enzymes, p. ex. kéfir, koumiss
23.
Nutritional compositions containing milk-derived peptides and uses thereof
Provided are nutritional compositions having a protein component that includes certain peptides and/or bioactive peptides. Further disclosed are nutritional composition having a protein source that includes intact protein, beta-casein enriched casein hydrolysate, and/or peptides weighing from about 500 Da to about 1,999 Da. The nutritional compositions disclosed are suitable for administration to pediatric subjects, such as infants.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A closure for a container is described where the container has an open end and a closed end, the closure engaging the open end of the container, wherein the closure comprises: a collar engaging the container; a lid connected to the collar by at least one hinge; wherein to facilitate engagement the collar extends over and surrounds the open end of the container such that an inner surface impinges on, or is immediately adjacent to, an outer surface of the open end of the container; wherein a plurality of beads extend outwardly from the inner surface of the collar to fixedly hold the collar in engagement with the container, wherein said beads are located substantially uniformly relative to each other and occupy less than 50% of the inner surface of the collar.
A method for enhancing cognitive development in a pediatric subject involving administering to the subject a nutritional composition which includes up to 7 g/100 Kcal of a fat or lipid; up to 5 g/100 Kcal of a protein or protein equivalent source; 0.25 g/100 Kcal to 16 g/100 Kcal of buttermilk; 5 mg/100 Kcal to 90 mg/100 Kcal of a source of long chain polyunsaturated fatty acid; and 0.015 g/100 Kcal to 1.5 g/100 Kcal of a prebiotic.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/714 - Cobalamines, p. ex. cyanocobalamine, vitamine B12
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/20 - Diminution de la valeur nutritiveProduits diététiques avec valeur nutritive réduite
Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
Provided are nutritional compositions having a protein component that includes certain peptides and/or bioactive peptides. Further disclosed are nutritional composition having a protein source that includes intact protein, beta-casein enriched casein hydrolysate, and/or peptides weighing from about 500 Da to about 1,999 Da. The nutritional compositions disclosed are suitable for administration to pediatric subjects, such as infants.
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
31.
DOCKING STATION INCLUDING LEVELER FOR RESEALABLE CONTAINER
The present disclosure relates to a docking station including a measuring device dock and a leveler. The docking station is suitable for use with container of multiple sizes and shapes. In certain embodiments, the docking station includes a flex prong for securing the docking station to the interior surface of a suitable container.
Provided are preterm infant formulas containing dietary butyrate. Further disclosed are methods for promoting or accelerating myelination and optimizing myelination development in preterm infants via administering the preterm infant formulas disclosed herein.
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present disclosure generally relates to pediatric nutritional compositions including galacto-oligosaccharide and human milk oligosaccharide or a precursor thereof. Further, the nutritional compositions may include GOS in combination with a first human milk oligosaccharide or precursor thereof and a second human milk oligosaccharide or precursor thereof. The disclosed nutritional compositions advantageously modify gut microbiome and improve select markers of immunity, brain structure, and gut function.
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present disclosure relates generally to device comprising a scaffold (10), a scoop leveler (20) and a scoop (30). The device may be manufactured in one or two pieces, by, e.g., injection molding. The device can be placed into a container where it is retained toward the top of the container. The container can be filled with flowable product, e.g., a granular substance such as a powder. The device's position toward the top of the container allows the device to stay above the product so that the scoop is easily located by a user.
The present disclosure relates generally to device comprising a scaffold, a scoop leveler and a scoop. The device may be manufactured in one or two pieces, by, e.g., injection molding. The device can be placed into a container where it is retained toward the top of the container. The container can be filled with flowable product, e.g., a granular substance such as a powder. The device's position toward the top of the container allows the device to stay above the product so that the scoop is easily located by a user.
The present disclosure relates generally to a measuring device comprising an upper body and a lower body. The upper body comprises a chamber having a top opening and a bottom opening, wherein a substance to be measured is placed in the top opening. The lower body fits inside and is slideable relative to the upper body to allow for the measurement of varying amounts of substance. The upper body may attach to a funnel to assist a user in filling the upper body with a substance to be measured, e.g., a powdered substance. The measuring device may be part of a measuring device and containment system.
Provided are nutritional compositions containing inositol. Further disclosed are methods for promoting optimal and functional synaptic development in a target subject via administering the nutritional composition containing inositol to the target subject. Further provided are methods for promoting brain development and overall brain health and function in a target subject.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/688 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols les deux composés hydroxylés ayant des atomes d'azote, p. ex. sphingomyélines
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
38.
NUTRITIONAL COMPOSITIONS CONTAINING BUTYRATE AND USES THEREOF
Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for promoting and/or accelerating myelination in a target subject via administering the nutritional composition containing dietary butyrate to the target subject.
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
The present disclosure generally relates to methods of preparing protein hydrolysates for use in pediatric nutritional compositions. Specifically, alpha-, beta- and/or kappa casein enriched casein, acid casein or caseinates can be hydrolyzed with proteases such as trypsin (trypsin-like), chymotrypsin (chymotrypsin-like), pepsin and/or plasmin to produce a hydrolysate that is close to the peptide composition of human breast milk.
Provided are nutritional compositions containing dietary butyrate or lactoferrin. Further disclosed are methods for reducing the incidence of obesity and metabolic syndrome in a target subject via administering the nutritional composition containing dietary butyrate to the target subject. Further provided are methods for improving adipose tissue functioning in a target subject.
A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/59 - Composés contenant le système cyclique du 9,10-séco-cyclopenta[a]hydrophénanthrène
The present disclosure generally relates to methods of preparing protein hydrolysates for use in pediatric nutritional compositions. Specifically, alpha-, beta- and/or kappa casein enriched casein, acid casein or caseinates can be hydrolyzed with proteases such as trypsin (trypsin-like), chymotrypsin (chymotrypsin-like), pepsin and/or plasmin to produce a hydrolysate that is close to the peptide composition of human breast milk.
This disclosure relates to methods of inducing adipocyte browning, supporting metabolic flexibility, and/or reducing detrimental WAT deposition or reducing WAT dysfunction in a subject by administering extensively hydrolyzed casein and/or fractions thereof ("eHC") to the subject, and/or by administering a long chain polyunsaturated fatty acid (e.g., docosahexaenoic acid and/or arachidonic acid) to the subject.
A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A container assembly (2) includes a main container (4) having an opening (6). A cap (8) closes the opening. An externally open recess (10) on the main container or the cap receives a tub (12). Removable packaging (14) is disposed around the container assembly such that the tub is retained in the recess. The main container may include a liquid nutritional composition (20). The tub may include a heat sensitive material (22), such as a probiotic or lactoferrin for addition to the main container by a user.
B65D 75/00 - Paquets comportant des objets ou matériaux partiellement ou complètement enfermés dans des bandelettes, des feuilles, des flans, des tubes ou des bandes en matériau souple mince, p. ex. dans des enveloppes pliées
B65D 81/32 - Réceptacles, éléments d'emballage ou paquets pour contenus présentant des problèmes particuliers de stockage ou de transport ou adaptés pour servir à d'autres fins que l'emballage après avoir été vidés de leur contenu pour emballer plusieurs matériaux différents qui doivent être maintenus séparés avant d’être mélangés
B65D 51/28 - Fermetures non prévues ailleurs combinées avec dispositifs auxiliaires pour des buts autres que la fermeture avec réceptacles auxiliaires pour objets ou matériaux supplémentaires
44.
NUTRITIONAL COMPOSITIONS PROVIDING DIETARY MANAGEMENT OF COLIC
A method for reducing the incidence of colic in a pediatric subject is presented, the method including administering to a subject a nutritional composition having about 1 x 103 to about 1 x 1012 cfu/100 kcal of LA metabolizing probiotic; up to about 7 g/100 kcal of a fat or lipid; up to about 5 g/100 kcal of a protein or protein equivalent source; about 0.06 g/100 kcal to about 1.5 g/100 kcal of enriched milk product; about 5mg/100 kcal to about 90 mg/100 kcal of a source of long chain polyunsaturated fatty acids; and about 0.015 g/100 kcal to about 1.5 g/100 kcal of a prebiotic composition.
The disclosure relates to a measuring device for a granulated product, including a top component comprising a leveling component and a clump-breaking component and a bottom component comprising a scoop and a handle. The measuring device allows a user to remove excess product from the scoop by moving the leveling component along the opening of the scoop. Further, the clump-breaking component serves to break the clump of product that forms in the scoop upon dispensing the product from the measuring device into a receptacle, which may contain a liquid. Breaking the clump of product improves the dissolution of the product into a liquid.
The present disclosure generally relates to personalized nutritional compositions for pediatric subjects, wherein the nutritional composition can include one of three distinct profiles of human milk oligosaccharides (HMOs). The present disclosure also relates to methods for determining the composition of HMOs present in or that would be present in the breast milk of the mother of a pediatric subject as determined by the mother's secretor status and/or Lewis blood group, and providing to the pediatric subject a nutritional composition comprising an HMO profile most similar to the HMOs present or that would be present in the breast milk of the subject's mother.
The present disclosure is directed to a container assembly (10) including a container (16) sealed by a closure (2). The container has a main chamber (1) in which a highly nutritive liquid food product can be filled and stored aseptically or through retort processing. The closure includes a separate chamber (7) in which a supplement sensitive to thermal processing of the liquid food product can be filled and stored. The container assembly permits the closure filled with the supplement to be attached to the container after severe thermal processing conditions have subsided, and permits the supplement to be conveniently and hygienically mixed with the liquid food product immediately prior to use.
B65D 51/28 - Fermetures non prévues ailleurs combinées avec dispositifs auxiliaires pour des buts autres que la fermeture avec réceptacles auxiliaires pour objets ou matériaux supplémentaires
B65D 41/62 - Couvercles extérieurs secondaires de protection en forme de capuchons, pour les éléments de fermeture
B65D 47/08 - Fermetures avec dispositifs de décharge autres que des pompes avec goulottes ou tubes de déversementFermetures avec dispositifs de décharge autres que des pompes avec tuyères ou passages pour la décharge ayant des fermetures articulées ou à charnières
48.
Nutritional compositions containing structured fat globules and uses thereof
The present disclosure relates to a lipid source for nutritional compositions, comprising an enriched lipid fraction which comprises structured fat globules. The enriched lipid fraction provides fat globules having a desired size and fatty acid composition and may be stabilized by components such as phospholipids, cholesterol, milk-fat globule membrane protein and combinations thereof. Additionally, the disclosure relates to methods of supporting lipid digestion in a pediatric subject by providing a nutritional composition comprising an enriched lipid fraction having structured fat globules that are more accessible to lipases. The chemical composition, size and structure of the fat globules may improve digestion. The disclosed nutritional compositions may provide additive and or/synergistic beneficial health effects.
Provided are nutritional compositions comprising a combination of a probiotic, dietary butyrate and/or a component for stimulating butyrate production in the human gut. Further disclosed are methods of accelerating tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
The disclosure relates to a measuring device for a granulated product, including a top component comprising a leveling component and a clump-breaking component and a bottom component comprising a scoop and a handle. The measuring device allows a user to remove excess product from the scoop by moving the leveling component along the opening of the scoop. Further, the clump-breaking component serves to break the clump of product that forms in the scoop upon dispensing the product from the measuring device into a receptacle, which may contain a liquid. Breaking the clump of product improves the dissolution of the product into a liquid.
Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome. The present disclosure in other embodiments, directed methods for reducing visceral pain in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic batch-cultivation process, such as LGG.
A nutritional compositions in a compressed solid form comprising about 5 to about 35% by weight of protein, about 5 to about 50% by weight percent of fat, and about 40 to about 70% by weight percent of carbohydrate, wherein the compressed solid form is readily dissolvable in water and has a moisture level of 4 to 17%. The nutritional composition, in certain embodiments, eliminates the need for scooping powder into narrow bottles, eliminates the need for transportation of loose powders for later reconstitution, and provides more precise serving sizes to ensure proper delivery of nutrients per feeding, while remaining readily dissolvable upon contact with a liquid. The disclosure further provides process for preparing a nutritional composition in a compressed solid form comprising cooling a powdered nutritional composition, contacting the cooled powdered nutritional composition with moisture, compressing the powdered nutritional composition under pressure, and drying the nutritional composition.
The present disclosure provides a composition and method for promoting functional neuronal development in pediatric subjects. The composition comprises in some embodiments up to about 7 g/100 Kcal of a fat or lipid source; up to about 5 g/100 Kcal of a protein source; about 3 mg/100 Kcal to about 50 mg/100 Kcal of phosphatidylethanolamine; about 0.15 mg/100 Kcal to about 75 mg/100 Kcal of sphingomyelin; and about 5 mg/100 Kcal to about 75 mg/100 Kcal of docosahexaenoic acid. The methods comprise, in some embodiments, administering the aforementioned composition to a pediatric subject.
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 31/688 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols les deux composés hydroxylés ayant des atomes d'azote, p. ex. sphingomyélines
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A23C 9/152 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre comportant des additifs
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A method for enhancing cognitive development in a pediatric subject involving administering to the subject a nutritional composition which includes up to 7 g/100 Kcal of a fat or lipid; up to 5 g/100 Kcal of a protein or protein equivalent source; 0.25 g/100 Kcal to 16 g/100 Kcal of buttermilk; 5 mg/100 Kcal to 90 mg/100 Kcal of a source of long chain polyunsaturated fatty acid; and 0.015 g/100 Kcal to 1.5 g/100 Kcal of a prebiotic.
A23C 17/00 - BabeurrePréparations à base de babeurre
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/714 - Cobalamines, p. ex. cyanocobalamine, vitamine B12
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/20 - Diminution de la valeur nutritiveProduits diététiques avec valeur nutritive réduite
A method for enhancing neurological health and development in a subject involving administering to the subject a nutritional composition including no greater than about 7 g/100 kcal of a fat or lipid source; no greater than about 7 g/100 kcal of a protein or protein equivalent source; at least about 5 g/100 kcal of a carbohydrate; and at least about 9 mg/100 kcal of inositol, wherein the ratio of exogenous inositol to inherent inositol is at least 50:50.
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A23L 1/29 - Modification de la qualité nutritive des aliments; Produits diététiques ( A23L 1/09 a priorité;substituts diététiques du sel A23L 1/22)
The present invention relates to a method of improving tolerance to hypoallergenic infant formulas. The method comprises neutralizing the pH of infant formulas containing ingredients exhibiting fishy, sour, or beany characteristics.
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23L 27/00 - ÉpicesAgents aromatiques ou condimentsÉdulcorants artificielsSels de tableSubstituts diététiques du selLeur préparation ou leur traitement
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A closure for a container for storing granulated powder. The closure includes a collar and a lid, a locking portion on the collar, and a locking portion on the lid, the collar locking portion operable to releasably engage the lid locking portion when the lid is in a closed position on the collar. The closure further includes a latch element on the collar and a latch element on the lid, the collar last element operable to releasably engage the lid locking portion. Some embodiments are operable to provide two audible sounds verifying the lid has been properly closed. Some embodiments include a modified elongated scoop having a length equal to the diameter of the inner perimeter of the lid for improved user experience scooping product from the bottom of a container.
A pillar shaped container for storing a granulated powder. The container has a sidewall having a cylindrical upper portion, a continuously concave curved intermediate portion and a cylindrical lower portion.
A47J 47/04 - Récipients clos pour produits alimentaires pour produits alimentaires granulés
B65D 8/00 - Réceptacles de section transversale courbe, dont le corps est formé par jonction ou liaison de plusieurs composants rigides, ou sensiblement rigides, constitués en totalité ou principalement en métal, en matière plastique, en bois ou en un matériau de remplacement
67.
Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
The present disclosure generally provides pediatric nutritional compositions comprising a protein source comprising an intact milk protein and a partially hydrolyzed milk protein, wherein about 5% to about 25% of total nitrogen content of the composition is non-protein nitrogen. The pediatric nutritional compositions described herein also comprise a fat source and a carbohydrate source. The partially hydrolyzed protein source, in certain embodiments, provides peptides that have similar structure and function to the peptides found in human milk.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
The present disclosure relates to milk-based nutritional compositions comprising lactoferrin and/or a prebiotic component, wherein, when combined, the lactoferrin and prebiotic component may exhibit additive or synergistic beneficial effects on the health and development of a pediatric subject. The disclosure further relates to methods comprising the administration of said milk-based nutritional compositions to pediatric subjects.
A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
A23L 1/29 - Modification de la qualité nutritive des aliments; Produits diététiques ( A23L 1/09 a priorité;substituts diététiques du sel A23L 1/22)
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
A composition and method for enhancing brain development in a pediatric subject, the method including administering to the pediatric subject a nutritional composition having up to about 7 g/100 kcal of a fat or lipid source, wherein the fat or lipid source includes at least about 0.5 mg/100 kcal of milk or non-milk polar lipids; up to about 5 g/100 kcal of a protein source; at least about 15 mg/100 kcal of lactoferrin from a non-human source; about 0.015 g/100 kcal to about 0.15 g/100 kcal of a prebiotic composition including polydextrose and/or galactooligosaccharide; and at least about 5 mg/100 kcal of a source of long chain polyunsaturated fatty acids.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
The present disclosure relates to improved expanded bed adsorption processes for isolating proteins from milk sources. In particular embodiments, the present disclosure provides a process for isolating a milk protein, such as lactoferrin, from a milk source comprising establishing an expanded bed adsorption column comprising a particulate matrix, applying a milk source to the matrix, and eluting the lactoferrin from the matrix with an elution buffer comprising about 0.3 to about 2.0 M sodium chloride.
A23J 1/20 - Préparation des compositions à base de protéines pour l'alimentationOuverture des œufs par grandes quantités et séparation du jaune du blanc à partir du lait, p. ex. caséinePréparation des compositions à base de protéines pour l'alimentationOuverture des œufs par grandes quantités et séparation du jaune du blanc à partir du petit-lait
C07K 14/79 - Transferrines, p. ex. lactoferrines, ovotransferrines
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 9/08 - Oxydoréductases (1.), p. ex. luciférase agissant sur le peroxyde d'hydrogène comme accepteur (1.11)
The present disclosure provides a method for reducing the risk of autoimmune disease by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition, may reduce the symptoms of autoimmune disease and may be a treatment for autoimmune disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.
The present disclosure provides a method for activating adiponectin by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce risk of heart attack and help in maintaining healthy weight. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present disclosure relates to nutritional compositions including a protein equivalent source including a peptide component comprising selected peptides from Tables 1 and 2 disclosed herein. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the incidence of autoimmune disease and/or diabetes mellitus by providing said nutritional compositions to a target subject, which includes a pediatric subject.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
The present disclosure relates to nutritional compositions including a protein equivalent source that includes a peptide component comprising selected peptides. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of promoting healthy body weight in a target subject by stimulating adiponectin levels by providing the nutritional compositions disclosed herein to a target subject, which includes a pediatric subject.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.
The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
The present disclosure relates to a lipid source for nutritional compositions, comprising an enriched lipid fraction which comprises structured fat globules. The enriched lipid fraction provides fat globules having a desired size and fatty acid composition and may be stabilized by components such as phospholipids, cholesterol, milk-fat globule membrane protein and combinations thereof. Additionally, the disclosure relates to methods of supporting lipid digestion in a pediatric subject by providing a nutritional composition comprising an enriched lipid fraction having structured fat globules that are more accessible to lipases. The chemical composition, size and structure of the fat globules may improve digestion. The disclosed nutritional compositions may provide additive and or/synergistic beneficial health effects.
A23C 9/14 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre dans lesquelles la composition chimique du lait est modifiée par des traitements non chimiques
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
The present disclosure relates to a lipid source for nutritional compositions, comprising an enriched lipid fraction which comprises structured fat globules. The enriched lipid fraction provides fat globules having a desired size and fatty acid composition and may be stabilized by components such as phospholipids, cholesterol, milk-fat globule membrane protein and combinations thereof. Additionally, the disclosure relates to methods of supporting lipid digestion in a pediatric subject by providing a nutritional composition comprising an enriched lipid fraction having structured fat globules that are more accessible to lipases. The chemical composition, size and structure of the fat globules may improve digestion. The disclosed nutritional compositions may provide additive and or/synergistic beneficial health effects.
The present disclosure relates to nutritional compositions comprising a prebiotic component for inhibiting adherence of pathogens in the gastrointestinal tract of a subject and to the prebiotic component, which comprises galactooligosaccharide, polydextrose or any mixture thereof. The nutritional compositions of the present disclosure comprise a fat or lipid source, a protein source, and a carbohydrate source comprising an effective amount of the prebiotic component.
The present disclosure relates to milk-based nutritional compositions comprising lactoferrin and/or a prebiotic component, wherein, when combined, the lactoferrin and prebiotic component may exhibit additive or synergistic beneficial effects on the health and development of a pediatric subject. The disclosure further relates to methods comprising the administration of said milk-based nutritional compositions to pediatric subjects.
A23K 1/18 - spécialement conçus pour des animaux déterminés
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 38/14 - Peptides contenant des radicaux saccharideLeurs dérivés
An improved container provides a container body and a closure. In some embodiments, a scooping utensil retainer is disposed on the closure. The scooping utensil retainer includes opposing flanges protruding from the closure surface. A flange rib protrudes from the first flange into the flange gap, extending from the closure surface to the distal end of the flange. A tapered retainer gap is provided between flanges for resiliently clamping the handle of a scooping utensil. In some embodiments, the closure can include an annular ridge shaped for engaging a downwardly extending skirt on a like container when two like containers are vertically stacked. In some embodiments the container body includes an in-mold label affixed to a substantially straight side wall, the in-mold label covering at least about 95% of the exterior surface area of the container body.
The present disclosure relates to methods of reducing the onset of allergies. In certain embodiments, the method includes administering to an infant a nutritional composition that includes a fat or lipid source, a carbohydrate source, a protein source comprising whey and casein proteins and, optionally, a probiotic. In certain embodiments, the whey:casein ratio in the protein source is from about 50:50 to about 70:30 and the degree of hydrolysis of the proteins included in the protein source is from about 4% to about 10%.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A nutritional composition for improving the immunological function of a subject, including a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; and about 0.1 to about 1 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide which has a fermentation rate which is demonstrably slower than that of galacto-oligosaccharide.
The present invention is directed to a novel method for increasing the production of acetate, decreasing the production of butyrate, increasing the population and species of beneficial bacteria and slowing the rate of fermentation of prebiotics within the gut of a formula-fed infant. The method comprises administration of a therapeutically effective amount of PDX to the infant.
The present invention is directed to carotenoid compositions and methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administration of an effective amount of astaxanthin and beta-carotene.
A method for inhibiting the adhesion of at least one pathogen in the gastrointestinal tract of a human is disclosed herein. In certain embodiments, the method involves administering to the human a nutritional composition including a fat or lipid source, a protein source, a prebiotic composition that includes galactooligosaccharide and/or polydextrose and lactoferrin produced by a non-human source.
A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
The present disclosure provides compositions and methods for delivering nutrients to subjects requiring small-volume nutritional support, such as preterm infants. The compositions may comprise an emulsion of docosahexaenoic acid (DHA) and arachidonic acid (ARA). The nutritional compositions are useful, for example, in correcting nutritional deficiencies by increasing a subject's intake of nutrients, such as ω-3 or ω-6 long-chain polyunsaturated acids. The nutritional compositions are suitable for enteral delivery as a nutritional supplement or for oral delivery as a human milk or infant formula fortifier.
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A23L 1/29 - Modification de la qualité nutritive des aliments; Produits diététiques ( A23L 1/09 a priorité;substituts diététiques du sel A23L 1/22)
A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;
The present invention is directed to a container for delivering a nutritive substance. In an embodiment, the present invention comprises a container that protects a nutritive substance from contact with the contents of the container and from contact with the atmosphere until the consumer is ready to use or consume the product. When desired, a seal on the container is altered such that the nutritive substance can come into contact with the container contents, delivering the nutritive substance thereto.
A container system (100) for storing material includes a container (10) and a mating closure (18) having a tamper- evident ring (22) frangibly attached to the closure. The container includes a neck (14) having a container thread (16) and an annular rim (38) for engaging the tamper- evident ring when the closure is removed from the container. The neck includes one or more retaining structures (50) for engaging the tamper- evident ring during retort sterilization processing, packaging, shipping or handling. The retaining structure in some embodiments includes one or more ramps having multiple inclined surfaces (52, 56). Each inclined surface is oriented at an acute angle between about five and about forty- five degrees such that the tamper- evident ring can slip past the retaining structure when a threshold removal torque is applied. A method of sealing a container using a tamper- evident closure system is also provided.
A container system for storing material includes a container and a mating closure having a tamper-evident ring frangibly attached to the closure. The container includes a neck having a container thread and an annular rim for engaging the tamper-evident ring when the closure is removed from the container. In some embodiments, the neck includes one or more retaining structures for engaging the tamper-evident ring during retort sterilization processing, packaging, shipping or handling. The retaining structure in some embodiments includes one or more ramps having multiple inclined surfaces. Each inclined surface is oriented at an acute angle between about five and about forty-five degrees such that the tamper-evident ring can slip past the retaining structure when a threshold removal torque is applied. A method of sealing a container using a tamper-evident container system is also provided.
B65D 17/32 - Réceptacles rigides ou semi-rigides spécialement conçus pour être ouverts par coupage ou perçage, ou en perçant ou en déchirant des éléments ou des parties frangibles le long de lignes ou à partir de points de moindre résistance avec des éléments ou des parties non détachables
A refillable product dispenser system for powdered infant formula includes a reusable container (16) having an initial product bag (18) received in the container. Refills for the reusable container are provided in similar refill product bags which may be of lesser volume than the initial product bag. The refill bags may be packaged in a refill outer package (22) containing two or more refill bags (24, 26).
An improved container (10) provides a container body (12) and a closure (14). In some embodiments, a scooping utensil retainer (20) is disposed on the closure. The scooping utensil retainer includes opposing flanges (30, 32) protruding from the closure surface (18). A flange rib (34) protrudes from the first flange (30) into the flange gap, extending from the closure surface to the distal end of the flange. A tapered retainer gap (42) is provided between flanges for resiliently clamping the handle (24) of a scooping utensil (22). In some embodiments, the closure can include an annular ridge (110) shaped for engaging a downwardly extending skirt (98) on a like container when two like containers are vertically stacked. In some embodiments the container body includes an in-mold label (124) affixed to a substantially straight side wall, and covering at least about 95% of the exterior surface area of the container body.
A container for storing matter provides a container body (12) having a resilient flange (20) protruding outward therefrom to form a seal between the container body and a mating closure (14). The resilient flange (20) is deflected by the inner surface (30) of the mating closure to form a first releasable seal (44) between the closure (14) and the container body (12). The resilient flange (20) includes an aspect ratio of length divided by thickness. A second releasable seal (54) is formed in some embodiments between the upper edge of the side wall (16) and the closure (14) when the mating closure is positioned on the container body.
An improved container provides a container body and a closure. In some embodiments, a scooping utensil retainer is disposed on the closure. The scooping utensil retainer includes opposing flanges protruding from the closure surface. A flange rib protrudes from the first flange into the flange gap, extending from the closure surface to the distal end of the flange. A tapered retainer gap is provided between flanges for resiliently clamping the handle of a scooping utensil. In some embodiments, the closure can include an annular ridge shaped for engaging a downwardly extending skirt on a like container when two like containers are vertically stacked. In some embodiments the container body includes an in-mold label affixed to a substantially straight side wall, the in-mold label covering at least about 95% of the exterior surface area of the container body.
A container for storing matter provides a container body having a resilient flange protruding outward therefrom to form a seal between the container body and a mating closure. The resilient flange is deflected by the inner surface of the mating closure to form a first releasable seal between the closure and the container body. The resilient flange includes an aspect ratio of length divided by thickness. A second releasable seal is formed in some embodiments between the upper edge of the side wall and the closure when the mating closure is positioned on the container body.
The present disclosure relates to nutritional compositions for pediatric subjects, such as children's nutritional products and infant formulas, comprising a protein source, a fat source, a carbohydrate source, and a source of β-glucan.
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
A23C 9/20 - Produits diététiques à base de lait non couverts par les groupes
A23C 11/02 - Succédanés du lait, p. ex. compositions pour remplacer le lait dans le café au lait contenant au moins un composé d'origine non laitière comme source de matières grasses ou de protéines
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
The present disclosure provides formulations and methods for delivering water-soluble and lipid-soluble nutrients for preventing or correcting nutrient deficiencies to subjects requiring small-volume nutritional support, such as preterm infants. The formulations may comprise an emulsion of docosahexaenoic acid (DHA) stabilized by a protein emulsifier, such as alpha-lactalbumin, and may further comprise other valuable nutrients, such as arachidonic acid (ARA), arginine, glutamine, arginyl-glutamine dipeptide and/or alanyl-glutamine dipeptide. The formulation is useful, for example, for correcting nutritional deficiencies by increasing a subject's intake of nutrients such as omega-3 or omega-6 long-chain polyunsaturated acids, proteins, peptides, vitamins, minerals, other fatty acids, and/or essential amino acids. The nutritional formulation is suitable for enteral delivery and small-volume delivery via nasogastric tube, intragastric feeding, transpyloric administration and/or any other means of administration that result in the introduction of the nutritional formulation into the digestive tract of a subject.
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
Disclosed is the use of a composition comprising docosahexaenoic acid (DHA) and/or arachidonic acid (ARA) in human subjects that are on the typical 'Western-type" high-fat high-sugar diet. It was found, in a humanized animal model, that said composition is capable of compensating for one or more of the adverse health effects of said diet. Particularly, an effect was found in body weight reduction, without a lowering of food intake. The composition can be administered as an oral (pharmaceutical) dosage unit, as a nutritional supplement, or as a component in a food or drink.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
brevets
